Clinical uses of intravenous immunoglobulin

Jolles, Stephen; Sewell, William A.; Misbah, Siraj

doi:10.1111/j.1365-2249.2005.02834.x

Cited by 284 publications

(265 citation statements)

References 126 publications

(118 reference statements)

Supporting

Mentioning

254

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][5][6][7][8] Generally, IVIg therapy is considered safe. [9][10][11][12] There are some mild common side effects like headache, fever, and chills, which are mainly transitory in nature and often related to the speed of infusion.…”

Section: Introductionmentioning

confidence: 99%

Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor–independent way

Jarius

Eichhorn²,

Albert³

et al. 2007

Blood

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor–independent way

Jarius

Eichhorn²,

Albert³

et al. 2007

Blood

View full text Add to dashboard Cite

“…12 It is unknown whether or not combined treatment with intravenous immunoglobulin and steroids offers added benefit. 13 The diagnosis of small cell neuroendocrine carcinoma of the cervix depends on the combination of light microscopic and immunohistochemical analysis. 14 Immunohistochemical findings were positive 81.8% for neuron-specific enolase and 81.8% for protein gene product 9.5 (PGP 9.5); 72.7% for synaptophysin; 63.6% for chromogranin A; and 54.5% for neural cell adhesion molecule.…”

Section: Discussionmentioning

confidence: 99%

Chronic inflammatory demyelinating polyneuropathy, diagnosed as a paraneoplastic manifestation of small cell neuroendocrine carcinoma of the cervix

Chakrabarti

Roy

Mallik

et al. 2013

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Paraneoplastic syndrome frequently presents before cancer is diagnosed and can be associated with neoplastic disease that is not yet radiographically detectable. We report on the case of a 35-year-old woman who presented at the neurology department with complaints of insidious onset and gradually progressive weakness in all four limbs, which had lasted for the past six months. The weakness originally commenced in both lower limbs and was progressive, ascending in nature from distal to proximal. Both upper limbs were affected seven days later. Magnetic resonance imaging of the dorsal spine revealed long-segment T2 and short T1 inversion recovery (STIR) hyperintensity, suggestive of myelitis. Nerve conduction studies and an electromyogram suggested sensory motor polyneuropathy which affected all four limbs. On gynaecological check-up, a diagnosis of International Federation of Gynaecology and Obstetrics (FIGO) stage IIB carcinoma cervix was made. Histology diagnosed it as a case of small cell neuroendocrine carcinoma. Thus, a diagnosis of chronic inflammatory demyelinating polyneuropathy, arising as a paraneoplastic syndrome in the carcinoma cervix, was made. The patient was treated with chemotherapy, steroids and radical radiotherapy. She recovered partially from her motor deficiencies and completely from her sensory derangement, and was devoid of gynaecological complaints. The cancer growth regressed completely.Peer reviewed.

show abstract

“…The advance in sepsis therapy [10] targets an immune system and a host individual response to microbial agents. Commercial available intravenous immunoglobulins (IVIG) preparations are in use since 1950s [10,11]. Pentaglobin ® has polyvalent capabilities for modulating host immune response, and it has been developed and introduced into clinical practice during 1990s [7].…”

Section: Discussionmentioning

confidence: 99%

Experience with IgM-Enriched Immunoglobulins as Adjuvant Therapy in Septic Patient after Redo Cardiac Surgery

Stojkovic¹

2015

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Infective endocarditis after combined mitral valve repair and coronary artery bypass surgery, multi-organ failure and sepsis, were treated with mitral valve replacement, antibiotics and adjunctive therapy. Sepsis caused by Gramnegative bacteria, was identified based on the grave clinical status, hemodynamic findings and high levels of proinflammatory cytokines. On the day of the redo surgery, the APACHE II and SOFA scores were 26 and 14, respectively. The IgM-enriched immunoglobulin Pentaglobin ® was administered on the first postoperative day after redo procedure. The cardiac index improved from 1.9 L/m 2 to 3.7 L/m 2 on the 1 st postoperative day, accompanied with increasing values of mixed venous oxygen saturation from 59.3% to 77%, while systemic vascular resistance 887 dyn·s/cm 5 was maintained by vasopressor agent. On the 4 th postoperative day the inotropes and pressors ceased. The acute physiology and chronic health evaluation (APACHE II) score and sequential organ failure assessment (SOFA) score decreased to 10 and 2, respectively. The prompt improvement in patient's general clinical condition, stabilised hemodynamic parameters, balanced perfusion and oxygen pattern, accompanied by notable reduction of pro-inflammatory cytokine expression, were the outcome of the presented therapeutic approach.

show abstract

Clinical uses of intravenous immunoglobulin

Cited by 284 publications

References 126 publications

Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor–independent way

Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor–independent way

Chronic inflammatory demyelinating polyneuropathy, diagnosed as a paraneoplastic manifestation of small cell neuroendocrine carcinoma of the cervix

Experience with IgM-Enriched Immunoglobulins as Adjuvant Therapy in Septic Patient after Redo Cardiac Surgery

Contact Info

Product

Resources

About